All articles tagged with #mounjaro
Rosie O'Donnell disclosed in a Substack essay that she underwent a lower deep plane facelift in January and shared before-and-after photos. She says losing 50 pounds on the weight‑loss drug Mounjaro prompted a shift in her views on cosmetic surgery, and that the procedure left her looking and feeling more rested without changing who she is—despite little external notice—and it led her to question rigid feminist ideas about aging.
A BuzzFeed News piece compiles Reddit anecdotes about stopping GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) and notes a BMJ meta-analysis finding that people who stop weight loss meds regain weight about four times as fast as those leaving behavioral programs, typically returning to baseline in about 1.7 years. The responses span a spectrum: hunger and food cravings return; some report hair loss or energy dips; many regain weight, but others credit lasting lifestyle changes like mindful eating, calorie tracking, and regular exercise for maintaining weight or easing off gradually. The piece highlights ongoing questions about whether GLP-1s are a temporary boost or a long term tool, and invites more personal experiences.
Eli Lilly more than doubled its Q1 profits as demand for obesity and diabetes medications drove revenue higher, with Mounjaro sales at $8.7bn and Zepbound at $4.2bn (up 80%), prompting a raised outlook. Foundayo was approved and launched this month but isn’t included in the quarter’s figures. Shares rose about 9%, and Lilly faces competitive pressure from Novo Nordisk while Medicare deals helped push Zepbound prices down even as volumes grew; investors will watch for weekly prescription data and updates on Foundayo’s performance.
Eli Lilly beat Q1 estimates with about $19.8B in revenue and $8.55 in adjusted EPS, powered by 125% growth in Mounjaro to $8.66B worldwide and $4.2B in U.S. sales, and $4.16B in U.S. Zepbound sales. The results prompted a $2B raise to full-year revenue guidance to $82–85B and higher adjusted EPS of $35.50–$37. Foundayo, the obesity GLP-1 pill, launched in Q2 and isn’t included in this report. Lilly maintains roughly 60% of the U.S. GLP-1 market, but faces pricing pressure and upcoming Medicare coverage changes as global GLP-1 use could reach about 30M by end-2026.
Eli Lilly issued a public warning about potential patient safety risks from compounded tirzepatide mixed with vitamin B12, including a newly identified impurity with unknown short- and long-term effects. The company says these compounded tirzepatide-B12 products lack safety monitoring and adverse-event reporting, has alerted the FDA, and urges patients to discuss alternatives with their physicians. Lilly also cautions about broader safety issues and contaminants in other unregulated tirzepatide knockoffs and calls for regulator action to curb mass compounding in favor of FDA-approved therapies like Mounjaro and Zepbound.
GLP-1 weight‑loss drugs like Ozempic, Wegovy, and Mounjaro are being linked to a new side effect: persistent itching that can disrupt sleep. While mild, local skin reactions at injection sites are common, widespread itching may signal sensitivity and could lead patients to pause or stop treatment and seek medical advice.
Eli Lilly unveils Employer Connect to help employers cover obesity medicines by connecting them with 15+ program administrators and offering a net price of $449 per month for a new Zepbound dose, aiming to lower employee out-of-pocket costs while giving employers design flexibility and price visibility; the move comes as Medicare coverage for these drugs is set to expand later this year and some firms may opt in gradually.
A Daily Mail Health feature follows Karen Holman, who used GLP-1 medications Ozempic and then Mounjaro via telehealth weight-loss program Mosh to combat trauma-driven overeating. She shed about 12 kg in four months, and blood tests showed her fatty liver reversing with liver markers returning to normal. Now weighing roughly 58–60 kg, she reports major relief from lifelong back pain and renewed energy. Medical experts explain GLP-1 meds curb appetite by slowing stomach emptying and altering brain hunger signals, and emphasize better outcomes when combined with structured lifestyle support. The piece also notes ongoing public debate about these medications and the role of behavioral/trauma-informed care in sustainable weight loss.
Brian Kinsella, who has privately used Mounjaro since December 2024, says he has lost more than 44.5 kg (seven stone) at up to £1,000 a year, highlighting uneven access as England’s NHS rolls out weight‑loss drugs. GPs are to receive £3,000 annually to prescribe these treatments, but since a limited NHS rollout began in June last year not all practices prescribe them. Kinsella expects the new incentives won’t help much due to workload and the system’s complexity, noting the requirement for two 85‑minute consultations, a 20‑minute follow‑up every four weeks, and a 60‑minute dietitian appointment. He calls the situation a “postcode lottery” and says a mechanism is needed to widen access to this drug.
England’s health strategy will pay GPs £3,000 a year plus about £1,000 for referring patients to weight‑loss programmes to increase NHS prescriptions of the drug Mounjaro; Wegovy remains prescribed only through NHS weight‑loss services. Access to these drugs on the NHS remains tightly restricted (BMI thresholds and health conditions), with rollout described as patchy. Experts say the incentives may help access but won’t widen eligibility, and concerns about workload and realistic patient eligibility persist as the NHS aims to shift toward prevention and reach an expected 220,000 Mounjaro users by 2028.
After Aishwarya Mohanraj’s Mounjaro confession, Soha Ali Khan discusses price with doctors: lower doses around Rs 12,000 per month (recently down to about Rs 10,000), higher doses about Rs 20,000–22,000, with overall monthly costs roughly Rs 12,000–20,000; prices are expected to fall as more companies produce them, but not everyone qualifies—BMI thresholds and co-morbid conditions determine eligibility, and medical supervision is essential due to side effects.
Two women with advanced fatty liver disease and fibrosis reportedly saw reversal of liver damage after using Mounjaro, a GLP-1 weight-loss drug. The case adds to growing evidence that treating obesity-related liver disease can reverse scar tissue, but NHS approval is still pending and access remains costly, underscoring the need for more research.
Eli Lilly posted 4Q25 sales of $19.3 billion, up 43%, driven by Zepbound at $4.3 billion (up 123%) and Mounjaro at $7.4 billion (up 110%), beating estimates with $11.7 billion from the two drugs. The company guided 2026 revenue of $80–83 billion and adjusted EPS of $33.50–$35.00, signaling ongoing growth even as Novo Nordisk anticipates a 5–13% 2026 decline. Lilly also struck a most‑favored‑nations deal for discounts via TrumpRx, and its stock rose in premarket trading.
Tianna Moon, a 30-year-old from East Anglia, says her 34NN breasts keep growing due to gigantomastia—a rare condition—after shedding weight on the drug Mounjaro; diagnosed in 2025, she struggles to find bras, experiences back and rib pain, and has had a private gastric sleeve to ease pain. Now at 14 stone, she considers reduction surgery while earning around £10,000 a month on OnlyFans, and she faces online skepticism about her diagnosis.
Eli Lilly reported Q4 2025 revenue of $19.3B, up 43% y/y, with GAAP EPS of $7.39 and non-GAAP EPS of $7.54, driven by strong demand for Mounjaro and Zepbound. The company highlighted regulatory progress (FDA approval of Kwikpen for tirzepatide and expanded Jaypirca indication) and a 2026 revenue guidance of $80–$83B with non-GAAP EPS of $33.50–$35.00, along with ongoing obesity/diabetes pipeline developments and a U.S. government agreement to expand access to obesity medicines.